You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the VONJO (pacritinib citrate) Drug Profile, 2024 PDF Report in the Report Store ~

VONJO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vonjo patents expire, and when can generic versions of Vonjo launch?

Vonjo is a drug marketed by Cti Biopharma Corp and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-seven patent family members in twenty-seven countries.

The generic ingredient in VONJO is pacritinib citrate. One supplier is listed for this compound. Additional details are available on the pacritinib citrate profile page.

DrugPatentWatch® Generic Entry Outlook for Vonjo

Vonjo will be eligible for patent challenges on February 28, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 25, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for VONJO
International Patents:77
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 2
Patent Applications: 3
Drug Prices: Drug price information for VONJO
What excipients (inactive ingredients) are in VONJO?VONJO excipients list
DailyMed Link:VONJO at DailyMed
Drug patent expirations by year for VONJO
Drug Prices for VONJO

See drug prices for VONJO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VONJO
Generic Entry Date for VONJO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VONJO

VONJO is protected by six US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VONJO is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VONJO

Oxygen linked pyrimidine derivatives
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)

Oxygen linked pyrimidine derivatives
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)

Oxygen linked pyrimidine derivatives
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)

Oxygen linked pyrimidine derivatives
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB

FDA Regulatory Exclusivity protecting VONJO

TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L
Exclusivity Expiration: ⤷  Try a Trial

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cti Biopharma Corp VONJO pacritinib citrate CAPSULE;ORAL 208712-001 Feb 28, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Cti Biopharma Corp VONJO pacritinib citrate CAPSULE;ORAL 208712-001 Feb 28, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Cti Biopharma Corp VONJO pacritinib citrate CAPSULE;ORAL 208712-001 Feb 28, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VONJO

When does loss-of-exclusivity occur for VONJO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4724
Estimated Expiration: ⤷  Try a Trial

Patent: 4133
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 09325147
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0922736
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 46058
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2282148
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0150428
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 76499
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 76499
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 61877
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 9379
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 69748
Estimated Expiration: ⤷  Try a Trial

Patent: 12511571
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 0005
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 11006206
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 3223
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1 (2,6).1(8, 12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 76499
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 76499
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 27970
Estimated Expiration: ⤷  Try a Trial

Patent: 11126173
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 1907
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1104032
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1729918
Estimated Expiration: ⤷  Try a Trial

Patent: 110106344
Patent: 11- (2-PYRROLIDIN-1-YL-ETHOXY) -14, 19-DIOXA-5, 7, 26-TRIAZA-TETRACYCLO [19. 3. 1. 1 (2, 6) 1 (8, 12)]HEPTACOSA-1 (25), 2 (26), 3, 5, 8, 10, 12 (27) J16, 21, 23-DECAENE CITRATE SALT
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 36558
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 49705
Estimated Expiration: ⤷  Try a Trial

Patent: 1028426
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VONJO around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1123282 氧連接的嘧啶衍生物 (OXYGEN LINKED PYRIMIDINE DERIVATIVES) ⤷  Try a Trial
South Korea 101729918 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2010068181 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.